What one share of Pliant Therapeutics holds
We are a clinical-stage biopharmaceutical company focused on discovering and developing integrin-based therapeutics. Our lead program is focused on the development of treatments for solid tumors by inhibiting integrin-mediated activation of transforming growth factor-β (TGF-β).
Pliant Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$1.50 |
|---|---|
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$1.15 |
| Dividends | $0.00 |
| Cash and investments | $0.40 |
| Debt | $0.00 |
| Book value | $2.37 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2019 | $35.14 | −$4.22 | $0.59 | −$2.29 | — | −$41.33 |
| 2020 | $1.96 | −$1.95 | $0.07 | −$1.82 | — | $7.96 |
| 2021 | $0.21 | −$2.71 | $0.05 | −$2.16 | $0.00 | $5.52 |
| 2022 | $0.23 | −$2.94 | $0.04 | −$2.29 | $0.00 | $6.40 |
| 2023 | $0.03 | −$2.75 | $0.02 | −$2.00 | $0.00 | $7.90 |
| 2024 | $0.00 | −$3.47 | $0.06 | −$2.63 | $0.00 | $5.00 |
| 2025 | $0.00 | −$2.43 | $0.01 | −$2.10 | $0.00 | $2.95 |
Common questions about Pliant Therapeutics
How much does one share of Pliant Therapeutics earn?
Over the last 12 months, Pliant Therapeutics lost $1.50 for each share.
Does Pliant Therapeutics pay a dividend?
Pliant Therapeutics didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Pliant Therapeutics’s book value per share?
Pliant Therapeutics’s book value is $2.37 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Pliant Therapeutics have?
Each share of Pliant Therapeutics has $0.40 of cash and investments and $0.00 of debt, as of June 30, 2026.
What is Pliant Therapeutics’s free cash flow per share?
−$1.15 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
Has Pliant Therapeutics bought back shares?
Pliant Therapeutics’s share count rose about 3680% from 2019 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.